StockpollyBeta
Get App
Popularity #3,201
BDTX · NASDAQ · Biotechnology

Black Diamond Therapeutics (BDTX)

Develops brain-penetrant therapies for EGFR-mutant lung cancer and glioblastoma.

$1.89
vs last close−0.09 (−4.59%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue0000007000000
Cost of revenue000000000000
Gross profit0000007000000
242120221818151311181112
Research & development1615131213121197677
8671056544445
General & administrative8671056544445
Other expenses000000000700
Operating income−24−21−20−22−18−1855−13−11−18−11−12
112232232222
Interest income001011111111
Other non-operating income0−1−2−2−3−2−2−3−2−7−21
Income before tax−23−19−18−20−16−1657−11−8−15−9−10
Net income from continuing operations−23−19−18−20−16−1657−11−8−15−9−10
Net income−23−19−18−20−16−1657−11−8−15−9−10
EPS, basic−$0.45−$0.41−$0.35−$0.36−$0.28−$0.28$1.00−$0.19−$0.15−$0.26−$0.16−$0.17
EPS, diluted−$0.45−$0.41−$0.35−$0.36−$0.28−$0.28$0.98−$0.19−$0.15−$0.26−$0.16−$0.17
Weighted average shares, basic514752555757575757575757
Weighted average shares, diluted514752555757585757575757
EBITDA−24−19−18−20−15−1657−10−8−10−9−13
Depreciation & amortization000000000000
EBIT−24−19−18−20−16−1657−11−8−10−9−13